Phase 2 Start

IBRX: Phase2_Start: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating the Safety and Efficacy of Nogapendekin Alfa Inbakicept (NAI) Plus Standard of Care (SOC) Compared to SOC Alone in Critically Ill Adults With Sepsis

Name: Phase2_Start: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating the Safety and Efficacy of Nogapendekin Alfa Inbakicept (NAI) Plus Standard of Care (SOC) Compared to SOC Alone in Critically Ill Adults With Sepsis
Start: 2026-10-15
End: 2026-10-15

October 15, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: October 15, 2026
Company: ImmunityBio, Inc. (IBRX)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 2 Start

Phase2_Start: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating the Safety and Efficacy of Nogapendekin Alfa Inbakicept (NAI) Plus Standard of Care (SOC) Compared to SOC Alone in Critically Ill Adults With Sepsis

October 15, 2026

IBRX overview →

Company: ImmunityBio, Inc. (IBRX)

Other upcoming events for IBRX

Phase 1 StartPhase1_Start: Open-Label, Single-Arm, Phase 1b Clinical Trial of NAI Plus Pembrolizumab With Short Course of Enfortumab Vedotin in Treatment-Naïve Participants With Metastatic Urothelial Carcinoma

Dec 1, 2026